1259522-46-7

Basic information

• Product Name: 2-ethyl-6-fluoro-3-(pyridin-2-yl)quinoline-4-carboxylic acid
• CAS NO: 1259522-46-7
• Molecular Weight: 296.301
• Mol File: 1259522-46-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-ethyl-6-fluoro-3-(pyridin-2-yl)quinoline-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-ethyl-6-fluoro-3-(pyridin-2-yl)quinoline-4-carboxylic acid(1259522-46-7)
• EPA Substance Registry System: 2-ethyl-6-fluoro-3-(pyridin-2-yl)quinoline-4-carboxylic acid(1259522-46-7)

Safety Data

• Hazardous Substances Data: 1259522-46-7(Hazardous Substances Data)

Upstream product

• 6303-73-7 1-(pyridin-2-yl)-butan-2-one 
• 443-69-6 5-fluoro-1H-indole-2,3-dione 
• 1259522-48-9 2-ethyl-6-fluoro-3-(pyridin-2-yl)quinoline-4-carboxamide 

Relevant articles and documents

Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-1430)

Optimization of the potency and pharmacokinetic profile of 2,3,4-trisubstituted quinoline, 4, led to the discovery of two potent, selective, and orally bioavailable PI3Kδ inhibitors, 6a (AM-0687) and 7 (AM-1430). On the basis of their improved profile, these analogs were selected for in vivo pharmacodynamic (PD) and efficacy experiments in animal models of inflammation. The in vivo PD studies, which were carried out in a mouse pAKT inhibition animal model, confirmed the observed potency of 6a and 7 in biochemical and cellular assays. Efficacy experiments in a keyhole limpet hemocyanin model in rats demonstrated that administration of either 6a or 7 resulted in a strong dose-dependent reduction of IgG and IgM specific antibodies. The excellent in vitro and in vivo profiles of these analogs make them suitable for further development.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.